A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema

@article{Callanan2016AM1,
  title={A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema},
  author={David G. Callanan and A. Michael Loewenstein and Sunil S. Patel and Pascale Massin and Borja Corc{\'o}stegui and Xiao-yan Li and Jenny Jiao and Yehia Hashad and Scott M. Whitcup},
  journal={Graefe's Archive for Clinical and Experimental Ophthalmology},
  year={2016},
  volume={255},
  pages={463-473}
}
To evaluate whether treatment with dexamethasone intravitreal implant (DEX implant) 0.7 mg every 5 months provides a similar average change in best-corrected visual acuity (BCVA) from baseline as ranibizumab 0.5 mg administered as per its European Summary of Product Characteristics in patients with diabetic macular edema (DME). This was a multicenter, open-label, 12-month, randomized, parallel-group, noninferiority study in patients with DME (one eye/patient). The primary efficacy measure was… CONTINUE READING
BETA
1
Twitter Mention

References

Publications referenced by this paper.
SHOWING 1-10 OF 36 REFERENCES

Similar Papers

Loading similar papers…